Skip to content
Catalyst

Silybum marianumFinding

Silybum marianum decreases aspartate aminotransferase

lowersModerate evidenceFindingreplicated ×1

01 · The sentence it was drawn from

“At day 56, the MT group had lower AST than the placebo group (p= 0.04).”
Quoted verbatim from A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL).
This finding among the 57 findings on its endpoint

Silybum marianum

Aspartate aminotransferase

lowers

Who
children aged 1-21 with acute lymphoblastic leukaemia in maintenance chemotherapy with grade 2 or higher hepatic toxicity; AST at day 56, four weeks after the 28-day course ended
Dose studied
silibinin target 5.1 mg/kg/day by weight band (80, 160, 240 or 320 mg/day), by mouth daily for 28 days

Moderate evidencePMID 20014183 · 2010

02 · The study

Study
RCT
Duration
4 weeks

Evidence, by strength

  • strong
  • moderatethis finding
  • limited
  • very limited
  • insufficient

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M7FQ383PHS9FCC6PFAD60ZQJ